Study of Levosimendan Before Tricuspid Valve Surgery in Patients with Right Ventricular Dysfunction

1 1 1

What is this study about?

This study focuses on patients who need surgery for tricuspid regurgitation, a heart condition where one of the heart valves (the tricuspid valve) doesn’t close properly, causing blood to flow backward. The study examines the effectiveness of a medication called levosimendan (ZIMINO) compared to placebo in preventing complications after heart surgery.

The purpose of this research is to determine if giving levosimendan before surgery can help prevent a condition called low cardiac output syndrome, which occurs when the heart cannot pump enough blood to meet the body’s needs after surgery. During the study, patients will receive either levosimendan or placebo through an intravenous infusion before their tricuspid valve surgery.

The medication or placebo will be given as a single treatment before the surgery. After the operation, patients will be monitored for 90 days to check for signs of heart-related complications, including the need for additional medications to support heart function, the use of devices to help the heart pump blood, or the need for special treatments to support kidney function.

1 Initial treatment administration

You will receive either levosimendan or placebo (5% glucose solution) through an intravenous infusion before your tricuspid valve surgery

The medical team will administer the treatment in preparation for your surgical procedure

2 Surgical procedure

You will undergo surgery to correct your tricuspid valve condition

The surgical team will perform the necessary corrections to address the moderate to severe tricuspid regurgitation

3 Post-surgery monitoring – first 48 hours

The medical team will monitor your heart function

Your blood pressure and other vital signs will be regularly checked

The medical staff will assess if you require any additional support medications

4 Intensive care unit observation

Your recovery will be closely monitored in the intensive care unit

The medical team will assess your kidney function and overall recovery progress

Your heart function will continue to be evaluated

5 Extended follow-up period

Your health status will be monitored for a total of 90 days after the surgery

The medical team will track your recovery progress and any potential complications

A final assessment will be conducted at the end of the 90-day period

Who Can Join the Study?

  • Must be 18 years of age or older
  • Must provide written informed consent to participate in the study
  • Must be enrolled in the French healthcare system
  • Must be scheduled for heart surgery to correct moderate to severe tricuspid valve leakage (a condition where the valve between the heart’s right chambers doesn’t close properly)
  • Must have at least one of these signs of severe tricuspid valve leakage:
    • An effective regurgitant orifice (the size of the leaking area) larger than 20 square millimeters
    • A vena contracta width (the width of the leaking blood flow) greater than 7 millimeters
    • Abnormal blood flow pattern in the liver veins during heart contraction
  • Can be either male or female

Who Cannot Join the Study?

  • Age below 18 years or above 85 years
  • Severe liver dysfunction (problems with liver function)
  • Severe kidney failure requiring dialysis
  • Known allergic reactions to levosimendan or similar medications
  • Current pregnancy or breastfeeding
  • Unstable heart condition requiring emergency surgery
  • Participation in other clinical trials within the last 30 days
  • Severe low blood pressure (systolic blood pressure below 90 mmHg)
  • Severe heart rhythm disorders that are not controlled by medication
  • History of severe reactions to anesthesia
  • Inability to provide informed consent
  • Significant blood clotting disorders that increase risk of bleeding during surgery
  • Active infection or fever
  • Severe lung disease requiring oxygen therapy

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
University Hospital Of Clermont-Ferrand Clermont Ferrand France
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
Oncopole Claudius Regaud Toulouse France

Other Sites

Site Name City Country Status
Centre Hospitalier Universitaire Rouen Rouen France
Centre Hospitalier Universitaire De Poitiers Poitiers France
Chorale Du Centre Hospitalier De Lens Lens France
Centre Hospitalier Universitaire De Montpellier Montpellier France
Centre Hospitalier Universitaire De Nantes Nantes France
Hopital Saint Joseph Marseille France
Centre Hospitalier Universitaire Amiens Picardie Amiens France
Centre Hospitalier Universitaire De Rennes Rennes France
Centre Hospitalier Lyon Sud Pierre Benite France
Hopital Beaujon Clichy France
Cntmth Hrjfojnibgc Ugeogzrrrfmcf Ropyo Reims France
Imeketzv Mdsraxnszk Marcauhfgo Paris France
Ctgjpj Hdqtepnzxnf Rvmwytiy Uaivsfmrrueon Dx Tbjyf Tours France
Cylres Htbzkvwxzem Utmipowevgeap Dc Dyihl Dijon France
Byrvutzg Uphesjzlsx Hsukpfkk Crvirm Besançon France
Cakdmmwb Dj Mdhpcpyiyy Montpellier France
Gmzcrm Huwhknvwdiv Uwthcyxldqebp Pkjgx Ptbveweyuwi Ed Nkjdntqjswol Paris France
Hanltop Jikoqz Clvrwiy Mfeht Massy France
Svdhnci Dtvavwsbzkrmalbhtdjf Dn Cqgczc Ccgwwshqrwoxv Da Nfpz St Denis France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not yet recruiting
05.09.2022

Trial locations

Investigated drugs:

Levosimendan is a medication that helps improve heart function. It works by making the heart muscle contract more strongly and helps blood vessels relax. This medication is given before heart surgery to help prevent complications related to poor heart function, particularly in patients who have problems with their tricuspid valve (one of the heart valves). It’s especially useful for patients whose right side of the heart isn’t working as well as it should.

Tricuspid Regurgitation – A heart valve condition where the tricuspid valve doesn’t close properly, causing blood to flow backward into the right atrium when the right ventricle contracts. The condition can range from mild to severe, with moderate to severe cases causing the heart to work harder to pump blood effectively. The condition may develop gradually over time and can be related to other heart problems. When functional in nature, it occurs due to enlargement of the right ventricle or right atrium, rather than from direct valve damage. The condition can lead to fluid retention and decreased cardiac output.

Low Cardiac Output Syndrome – A condition where the heart cannot pump enough blood to meet the body’s needs. It is characterized by reduced blood flow from the heart, which can affect multiple organ systems. The condition can develop after heart surgery or in patients with severe heart conditions. The syndrome often requires supportive measures to maintain adequate circulation. It may be accompanied by symptoms such as fatigue, weakness, and decreased urine output.

Trial ID:
2024-516167-86-00
Protocol code:
APHP200072
NCT ID:
NCT05233202
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on Dapagliflozin for Reducing Atrial Fibrillation and Kidney Injury in Patients Awaiting Coronary Artery Bypass Surgery

    Recruiting

    1 1 1
    Investigated drugs:
    Czechia Denmark Sweden